Consider a long position in Biohaven (BHVN), as the recent stock drop below $9 is viewed as a significant overreaction to widely expected FDA news. The investment thesis is that the market has unfairly punished the stock, creating a contrarian buying opportunity with a reference entry price around $8.45. Conversely, a high-conviction short opportunity is identified in IonQ (IONQ) following its earnings report. The rationale for shorting IONQ is the belief that its revenue growth is inorganic and acquired, masking a weak underlying business. Lastly, Palantir (PLTR) is held as a core long-term position, signaling strong conviction despite its recent underperformance.

Biohaven (BHVN)

• The speaker has gone long on Biohaven (BHVN), a biotech company.
• The position was initiated after the stock dropped on what the speaker considers to be misunderstood "bad news."
  • The company's drug was rejected by the FDA, but this outcome was widely expected.
  • The speaker believes the market is overreacting, treating the failed drug as the company's most important asset, which he states it "most certainly is not."
• He has invested a significant amount, referring to it as an 80% position in his portfolio and having gone "all in."
• His average purchase price is $8.45.
• The investment thesis is that the stock has been unfairly punished and that long-term supporters of the company will likely "load up the boat," causing the price to recover.

Takeaways

• Bullish Sentiment: The speaker is very bullish on BHVN as a contrarian play.
• Investment Strategy: This is an example of buying a stock after negative news when you believe the market's reaction is exaggerated. The speaker believes the fundamental value of the company is intact despite the recent setback.
• Potential Catalyst: A potential positive driver would be the market realizing the rejected drug was not critical to the company's overall pipeline, leading to a price correction upwards.

Palantir (PLTR)

• The speaker is long on Palantir (PLTR).
• He states that PLTR is currently his biggest position.
• It is mentioned as the "only thing in my portfolio that's not cooperating," suggesting the stock has been underperforming recently relative to his other holdings.

Takeaways

• Bullish Sentiment: Despite its recent underperformance, the speaker maintains a large long position, indicating continued conviction.
• Position Sizing: The fact that it's his largest position highlights a high degree of confidence in the company's long-term prospects, even if no specific reasons were detailed in this transcript.

IonQ (IONQ) & Quantum Computing Sector

• The speaker has a strong bearish (negative) view on IonQ (IONQ) and other "second and third tier" quantum computing stocks.
• He refers to shorting these companies as "pretty great" and "pretty epic" because he considers them to be "low quality."
• After listening to the IonQ earnings call and reviewing the initial numbers, he calls it a "good short," stating "there's nothing in here that's useful or good."
• Critique of Revenue: He heavily scrutinizes IonQ's revenue growth, concluding that "they bought all the growth" through acquisitions. He analyzes the pro forma revenue numbers to show that organic growth is weak or non-existent.
  • He notes that the company's interest income is almost as high as its revenue, which he finds concerning.
• Trading Activity: The speaker is actively trying to short-sell IONQ stock in the after-hours market following the earnings release, anticipating a price drop of "10% or something."
• Other Quantum Stocks Mentioned:
  • D-Wave (QBTS) and Rigetti (RGTI) are categorized as "second tier" quantum stocks. The speaker notes he has losing short positions on both.
  • IBM is mentioned as a "first tier" quantum company.

Takeaways

• Bearish Sentiment: The speaker is actively shorting IONQ and is bearish on the broader speculative quantum computing sector, excluding established players like IBM.
• Investment Thesis (Short): The thesis for shorting IONQ is that its impressive reported revenue growth is not organic but rather engineered through a series of acquisitions. The speaker believes the underlying business is weak and the stock is overvalued, calling the pump "over."
• Risk for Investors: The speaker's analysis suggests investors should be cautious about headline revenue numbers from companies like IONQ and should investigate the source of that growth (organic vs. acquired). The high stock-based compensation and large losses are also potential red flags mentioned.

Sarepta (SRPT)

• The speaker had a successful long trade on Sarepta (SRPT).
• The stock had a "huge bounce" and a "real nice recovery," which contributed significantly to his portfolio's gains.
• He sold a portion of his position quickly ("in five minutes") to lock in profits but mentions he is "still in some Sarepta."

Takeaways

• Bullish Sentiment: The speaker is positive on SRPT, viewing its recovery as a case of "cooler heads prevail."
• Trading Strategy: This demonstrates a strategy of taking partial profits on a winning position after a sharp upward move while retaining a smaller position for potential further gains.

Other Short Positions

• The speaker mentions several other stocks he is shorting, generally based on the idea that they are "low quality companies."
• LAES (Ticker Unconfirmed): He is short this stock and added to his position during the stream.
• BTQ (Ticker Unconfirmed): Mentioned as a "better short" because it is a "low quality" company.
• Okla (Ticker Unconfirmed): Mentioned as a "probably a good short."
• Cure (Ticker Unconfirmed): He has a "very small" short position, noting it has the "same problem as Biohaven" (likely related to an FDA approval issue).

Takeaways

• Bearish Strategy: The speaker actively shorts stocks he perceives as being fundamentally weak or low-quality.
• Risk Management: He notes his short position in "Cure" is very small, demonstrating the use of position sizing to manage risk in trades he may be less confident about.